System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Paolo Bossi is an expert in Oncology at IRCCS Humanitas Research Hospital (Italy). As of October 2026, ScienceLeadR ranks Paolo Bossi in the top 1% of experts worldwide for Squamous Cell Carcinoma of Head and Neck, Otorhinolaryngologic Neoplasms and Pharyngeal Diseases. Paolo Bossi has authored 650 publications, the most recent in 2026, and is an investigator in 38 clinical trials, 15 of them ongoing. SLR score: 2,858 (community average: 125). How the SLR is computed.

LeadR Profile

Paolo Bossi IRCCS Humanitas Research Hospital Italy
2 858 ScienceLeadR Reputation 2858

Unlock

Register Login
Network Map

Oncology

Subspecialties: Otolaryngology - Radiotherapy - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1995 - 2026
Source: PubMed

IRCCS Humanitas Research Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 650

Citations

Citations: 15 062 1st author: 109 Last author: 146 Unique author: 3

Main journals

Ann Oncol 67
Oral Oncol 54
J Clin Oncol 46
Support Care Cancer 38
Radiother Oncol 32

Best Journals

Ann Oncol 20
J Clin Oncol 19
Lancet Oncol 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations.
PMID 42933448 — neoplasms, nasopharyngeal carcinoma, therapeutics		Lancet Oncol Top journal20260
Symptom-based vs radiological follow-up in head and neck squamous cell carcinoma: A systematic review.
PMID 42924864 — cells, carcinoma, squamous cell, neoplasms, signs and symptoms, squamous cell carcinoma of head and neck, therapeutics		Tumori20260
Navigation-Guided Spatial Mapping of Subclinical Local Invasion in Sinonasal and Nasopharyngeal Malignancies.
PMID 42922403 — carcinoma, squamous cell, probability, hypersensitivity, neoplasms, biopsy, histology, precision medicine, head and neck neoplasms		Int Forum Allergy Rhinol20260
Risk Factors and Therapeutic Consequences of Virologic Failure With Long-Acting Cabotegravir Plus Rilpivirine in the Dat'AIDS Cohort.
PMID 42873188 — viremia, rilpivirine, risk factors, therapeutics, communicable diseases, drug resistance, dolutegravir		Clin Infect Dis20260
Clinical Management of Oral Potentially Malignant Disorders: State of the Art Review and Proposal for a New Framework.
PMID 42735806 — oral submucous fibrosis, leukoplakia, neoplasms, research		Crit Rev Oncol Hematol20260

Clinical Studies 38

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7 Study Chair: 1

By phase:

Phase 2 24
N/A 7
Phase 3 7

By status:

Completed 9
Recruiting 9
Active not recruiting 6
Unknown 5
Not yet recruiting 4
Terminated 3
Suspended 1
Withdrawn 1

By type:

Interventional 36
Observational 2

By Monocentric/Multicentric:

monocentric 11
multicentric2to4 2
multicentric5to9 5
multicentricup10 20

Main Topics

Cohort/Consortium Investigators 12

Ongoing Clinical Trials

15 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A phase 3 study to evaluate petosemtamab vs investigator s choice in previously treated metastatic recurrent head and neck cancer
2023-510322-32-00 — cells, safety, carcinoma, squamous cell, neoplasms, squamous cell carcinoma of head and neck, head and neck neoplasms, therapeutics, carcinoma, head, neck		Phase 3Active not recruiting2025
A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first line treatment of head and neck cancer
2023-510323-30-00 — cells, safety, carcinoma, squamous cell, neoplasms, squamous cell carcinoma of head and neck, head and neck neoplasms, therapeutics, carcinoma, head, neck		Phase 3Recruiting2025
L19IL2 L19TNF in patients with cutaneous squamous cell carcinoma
2025-523231-19-00 — cells, carcinoma, squamous cell, therapeutics, carcinoma, cutaneous squamous cell carcinoma		Phase 2Not yet recruiting2026
Toripalimab plus chemotherapy as first line treatment for recurrent and or metastatic nasopharyngeal cancer safety and activity in non endemic population
2025-522472-85-00 — safety, neoplasms, drug therapy, nasopharyngeal neoplasms, therapeutics, chemotherapy, carcinoma		Phase 3Recruiting2026
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent Metastatic Head and Neck Cancer
2025-521917-24-00 — cells, carcinoma, squamous cell, neoplasms, fluorouracil, squamous cell carcinoma of head and neck, head and neck neoplasms, therapeutics, carboplatin, carcinoma, head, neck		Phase 3Not yet recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS